Revenue Components (Tables)

3 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

The following table provides information about the Company’s revenues (in thousands):


	Three Months Ended June 30,
	2022		2021
Revenues:
Product revenue, net:
ORGOVYX	$	36,034	$	10,479
MYFEMBREE	3,999		1,075
Richter product supply and royalties	1,318		—
Total product revenue, net	41,351		11,554
Pfizer collaboration revenue:
Amortization of upfront payment	20,974		20,974
Amortization of regulatory milestone	4,167		8,535
Total Pfizer collaboration revenue	25,141		29,509
Accord license revenue	50,000		—
Total revenues	$	116,492	$	41,063

Summary Of Categories Of Discounts And Allowances

The activities and ending balances for each significant category of discounts and allowances (which constitutes variable consideration) for the three months ended June 30, 2022 were as follows (in thousands):


	Reserve -government and other incentives		Chargebacks and administrative fees		Returns		Sales Discounts		Total
Balance as of March 31, 2022	$	13,734	$	2,628	$	3,028	$	486	$	19,876
Provision related to sales in the current year	23,742		6,469		815		1,146		32,172
Adjustments related to prior year sales	1,785		(389)		—		—		1,396
Credits and payments made during the current year	(21,185)		(5,335)		(2)		(1,074)		(27,596)
Balance as of June 30, 2022	$	18,076	$	3,373	$	3,841	$	558	$	25,848

The total reserves described above are summarized as components of the Company’s unaudited condensed consolidated balance sheets as follows (in thousands):


	June 30, 2022		March 31, 2022
Reduction of accounts receivable, net	$	558	$	486
Component of accrued expenses and other current liabilities	25,290		19,390
Total revenue-related reserves	$	25,848	$	19,876